Treatment of Pan-Resistant Morganella morganii UTI in a 75-Year-Old Female
Treat with intravenous meropenem 1 gram every 8 hours for 5-7 days, with dose adjustment based on renal function. This is the only viable option given pan-resistance except to meropenem, and carbapenems remain the cornerstone for multidrug-resistant Enterobacterales urinary tract infections.
Dosing and Duration
For complicated UTI due to carbapenem-resistant or multidrug-resistant Enterobacterales, the 2022 guidelines recommend 5-7 days of treatment 1. Given this is Morganella morganii (an Enterobacterales family member) with extreme resistance:
- Standard dosing: Meropenem 1 gram IV every 8 hours 2
- Critical consideration for elderly: At 75 years old, assess creatinine clearance immediately 2
- If CrCl ≤50 mL/min: dose reduction is mandatory 2
- If CrCl 26-50 mL/min: 1 gram every 12 hours
- If CrCl 10-25 mL/min: 500 mg every 12 hours
- If CrCl <10 mL/min: 500 mg every 24 hours
Key Clinical Considerations
Why Meropenem Over Other Options
The 2024 EAU guidelines specify that for uncomplicated pyelonephritis with multidrug-resistant organisms, carbapenems should only be considered when early culture results indicate resistance to other agents 3. Your patient meets this criterion with pan-resistance. Among carbapenems:
- Meropenem achieves excellent urinary concentrations 2
- The FDA label confirms efficacy for complicated UTIs 2
- Recent data shows meropenem maintains >98% susceptibility against M. morganii isolates 4
Combination Therapy Consideration
While monotherapy is appropriate for UTI, consider adding an aminoglycoside (gentamicin 5-7 mg/kg/day IV once daily) if the patient is clinically unstable 1. The 2022 MDR guidelines specifically recommend aminoglycosides for complicated UTIs due to carbapenem-resistant Enterobacterales 1. Recent research demonstrates synergy between meropenem and aminoglycosides against resistant M. morganii 5.
However, in a stable 75-year-old with isolated UTI, meropenem monotherapy is sufficient 1. Combination therapy increases nephrotoxicity risk in elderly patients.
Critical Pitfalls to Avoid
1. Seizure Risk in Elderly
Meropenem carries seizure risk, particularly in elderly patients with renal impairment 2. Monitor for:
- Focal tremors, myoclonus, or altered mental status
- Continue any existing anti-convulsant therapy
- If seizures occur, reduce dose or discontinue 2
2. Drug Interaction Alert
If the patient takes valproic acid or divalproex for seizure control, do NOT use meropenem 2. Carbapenems dramatically reduce valproic acid levels, causing breakthrough seizures. In this scenario, you would need infectious disease consultation for alternative strategies, though options are extremely limited with pan-resistance.
3. Thrombocytopenia Monitoring
In elderly patients with renal impairment, monitor platelet counts as thrombocytopenia has been reported with meropenem 2.
4. Source Control
Ensure no urinary obstruction, retained catheter, or abscess. The 2024 EAU guidelines emphasize that complicated UTI management requires addressing anatomic abnormalities 3. Obtain renal ultrasound if not already done.
Resistance Surveillance Concerns
Recent data shows alarming trends in M. morganii resistance:
- Carbapenem resistance increased significantly after 2022 4
- Some isolates now harbor KPC-2, NDM-1, or OXA-48 carbapenemases 6
- Mortality from M. morganii bacteremia reaches 41% 7
If the patient fails to improve within 72 hours, repeat cultures and consider:
- Carbapenemase production testing (though treatment options are nearly exhausted)
- Infectious disease consultation
- Potential for colistin-based combination therapy, though M. morganii has intrinsic colistin resistance 5
Alternative Considerations if Meropenem Fails
Given pan-resistance, options are severely limited. The 2022 MDR guidelines suggest for CRE with limited options 1, 8:
- Ceftazidime-avibactam 2.5 g IV q8h (if available and susceptible)
- Polymyxin-based combinations (though M. morganii is intrinsically colistin-resistant)
- High-dose extended-infusion meropenem (3-hour infusion) if MIC ≥8 mg/L 1
However, these are salvage options requiring susceptibility confirmation.
Monitoring Parameters
- Daily clinical assessment for symptom resolution
- Repeat urinalysis after 48-72 hours if not improving
- Renal function monitoring (especially in elderly) 2
- Neurological assessment for seizure precursors 2
- Platelet count if renal impairment present 2
The treatment duration of 5-7 days assumes prompt clinical response 1. If delayed response or bacteremia develops, extend to 10-14 days 1, 9.